New York Assembly Bill A10083

New York 2025-2026 Regular Session

• Introduced: 1/30/26
• Refer: 1/30/26

Caption

Relates to the dispensing of certain prescriptions

Summary

This bill amends the Education Law to further protect the privacy of people receiving mifepristone or misoprostol prescriptions. It changes labeling requirements so that these prescriptions may be dispensed without the dispenser’s name and address, and without the patient’s name and address on the label, so long as the label includes a prescription number or other identifying means. It also revises the related prescriber-request provision to allow dispensing without the owner’s name and address, the prescriber’s name, and the patient’s name and address on the label, again requiring that the information be recorded and maintained by the pharmacist. The bill requires pharmacists and other dispensers to keep logs containing the prescription number and identifying information, including the dispenser’s and patient’s names and addresses, for at least five years. It also preserves the ability of law enforcement to investigate criminal activity, but limits disclosure to records strictly necessary for that investigation. The act would take effect immediately.

Impact

The bill would amend sections 6807 and 6810 of the Education Law, narrowing what identifying information must appear on prescription labels for mifepristone and misoprostol while preserving internal recordkeeping obligations for pharmacists. It would affect pharmacies, prescribers, dispensers, patients obtaining medication abortion drugs or miscarriage-management medications, and potentially investigators seeking records in criminal inquiries. The practical effect is to increase confidentiality for these prescriptions while maintaining a paper trail for compliance and law-enforcement purposes.

Sentiment

There is no recorded committee transcript or vote history available for this bill, so the formal legislative sentiment cannot be directly measured from debate or roll call. Based on the bill’s text, the measure appears oriented toward privacy protection and access to reproductive-health medications, suggesting support from advocates of patient confidentiality and medication privacy. The bill was later stricken, which indicates it did not advance in the form introduced, but the available record does not show the reason or any recorded opposition.

Contention

The main point of contention is likely the balance between patient privacy and transparency in prescription labeling. Supporters would emphasize confidentiality for patients receiving mifepristone or misoprostol, while opponents or skeptical stakeholders may be concerned that reduced label information could complicate oversight, pharmacy accountability, or investigations. The bill attempts to address that concern by requiring record retention and allowing disclosure only when strictly necessary for criminal investigations.